Toggle Offcanvas
...
 
Adalimumab Tenders

Adalimumab Tenders

View Adalimumab tenders, RFPs and contracts. Bid on readily available Adalimumab tenders with the best and most comprehensive tendering platform, since 2002.

Bidding for Adalimumab tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Adalimumab.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Adalimumab market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Adalimumab tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

38 Live Notices for Adalimumab Tenders

Showing 1 to 20

Judicial Acquisition Of Medicines: Adalimumab, Romiplostatim
country Brazil
posting date13 Mar 2025
deadline28 Mar 2025
Adalimumab 40Mg Sol.Iny.Jrpautoin 1000020734
country Chile
posting date12 Mar 2025
deadline31 Mar 2025
010-Adquisition Of Adalimumab For The Children'S Hospital Dr. Roberto Del Rio Cfo
country Chile
posting date12 Mar 2025
deadline26 Mar 2025
Delivery Of Laboratory Reagents And Consumables For Diagnostic Tests And Lease Of Analyzers And Other Equipment.
country Poland
posting date11 Mar 2025
deadline10 Apr 2025
Delivery Of Laboratory Reagents And Consumables For Diagnostic Tests And Lease Of Analyzers And Other Equipment.
country Poland
posting date06 Mar 2025
deadline10 Apr 2025
Etanercept 25 Mg05 Ml Sol. Iny.Jrp 1000020733
country Chile
posting date06 Mar 2025
deadline17 Mar 2025
Supply Of The Humira® Medicine (Adalimumab) For The Continuation Of Current Treatments, Excluding The New Treatments (Doe) For All Osakidetza Service Organizations And Linked Health Centers.
country Spain
posting date04 Mar 2025
deadline19 Mar 2025
Oral And Injectable Ministerial Program Agreement For 6 Months
country Chile
posting date04 Mar 2025
deadline12 Mar 2025
Ministerial Program Agreement 2 Injectable For 6 Months
country Chile
posting date28 Feb 2025
deadline19 Mar 2025
Request For Information: Equipment And Reagents For The Analysis Of Biological Drug Assays
country Finland
posting date26 Feb 2025
deadline01 May 2025
Denosumab 60 Mgml Salt. Iny Jer Prem 1000020832
country Chile
posting date22 Feb 2025
deadline24 Mar 2025
Etanercept Druotept Supply Agreement Continuity Of Treatment For The Provincial Hospital Of Ovalle
country Chile
posting date22 Feb 2025
deadline12 Mar 2025
Purchase And Successive Delivery Of Medicinal Products For Drug And Chemotherapy Programs
country Poland
posting date12 Feb 2025
deadline17 Mar 2025
Purchase And Delivery Of Biological Medicines
country Poland
posting date12 Feb 2025
deadline19 Mar 2025
Prescription Service Drug Insurance Supplement Competition
country Saudi Arabia
posting date30 Jan 2025
deadline03 Nov 2025
Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Adalimumab (Atc Code According To Who: L04Ab04)
country Germany
posting date20 Jan 2025
deadline30 Nov 2026
Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Adalimumab (Atc Code According To Who: L04Ab04)
country Germany
posting date20 Jan 2025
deadline30 Nov 2026
Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Adalimumab (Atc Code According To Who: L04Ab04)
country Germany
posting date20 Jan 2025
deadline30 Nov 2026
Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Adalimumab (Atc Code According To Who: L04Ab04)
country Germany
posting date20 Jan 2025
deadline30 Nov 2026
Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Adalimumab (Atc Code According To Who: L04Ab04)
country Germany
posting date21 Jan 2025
deadline30 Nov 2026

Share Share this page